SG10201704908SA - Cytotoxic T-Lymphocyte-Inducing Immunogens For Prevention, Treatment, And Diagnosis Of Dengue Virus Infection - Google Patents

Cytotoxic T-Lymphocyte-Inducing Immunogens For Prevention, Treatment, And Diagnosis Of Dengue Virus Infection

Info

Publication number
SG10201704908SA
SG10201704908SA SG10201704908SA SG10201704908SA SG10201704908SA SG 10201704908S A SG10201704908S A SG 10201704908SA SG 10201704908S A SG10201704908S A SG 10201704908SA SG 10201704908S A SG10201704908S A SG 10201704908SA SG 10201704908S A SG10201704908S A SG 10201704908SA
Authority
SG
Singapore
Prior art keywords
lymphocyte
cytotoxic
diagnosis
prevention
treatment
Prior art date
Application number
SG10201704908SA
Inventor
Ramila Philip
Original Assignee
Emergex Vaccines Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emergex Vaccines Holdings Ltd filed Critical Emergex Vaccines Holdings Ltd
Publication of SG10201704908SA publication Critical patent/SG10201704908SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A61K38/017—Hydrolysed proteins; Derivatives thereof from animals from blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
SG10201704908SA 2011-06-29 2012-06-28 Cytotoxic T-Lymphocyte-Inducing Immunogens For Prevention, Treatment, And Diagnosis Of Dengue Virus Infection SG10201704908SA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161502365P 2011-06-29 2011-06-29

Publications (1)

Publication Number Publication Date
SG10201704908SA true SG10201704908SA (en) 2017-07-28

Family

ID=47424544

Family Applications (2)

Application Number Title Priority Date Filing Date
SG2013086608A SG195115A1 (en) 2011-06-29 2012-06-28 Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of dengue virus infection
SG10201704908SA SG10201704908SA (en) 2011-06-29 2012-06-28 Cytotoxic T-Lymphocyte-Inducing Immunogens For Prevention, Treatment, And Diagnosis Of Dengue Virus Infection

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG2013086608A SG195115A1 (en) 2011-06-29 2012-06-28 Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of dengue virus infection

Country Status (5)

Country Link
US (3) US9637521B2 (en)
AU (1) AU2012275319A1 (en)
BR (1) BR112013032421A2 (en)
SG (2) SG195115A1 (en)
WO (1) WO2013003579A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9637521B2 (en) 2011-06-29 2017-05-02 Emergex Vaccines Holdings Limited Cytotoxic T lymphocyte inducing immunogens for prevention treatment and diagnosis of dengue virus infection
EP3228321B1 (en) 2011-09-13 2019-04-10 Immunotope, Inc. Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
WO2015175361A1 (en) * 2014-05-13 2015-11-19 Immunotope, Inc. Dengue virus specific multiple hla binding t cell epitopes for the use of universal vaccine development
TWI653049B (en) * 2016-10-21 2019-03-11 國立成功大學 Synthetic polypeptide, vaccine composition comprising the same, and use thereof
SG11202002044WA (en) 2017-09-21 2020-04-29 Emergex Vaccines Holding Ltd MHC Class I Associated Peptides for Prevention and Treatment of Zika Virus
JP2021509400A (en) * 2018-01-06 2021-03-25 イマージェクス ヴァクシンズ ホールディング リミテッドＥｍｅｒｇｅｘ Ｖａｃｃｉｎｅｓ Ｈｏｌｄｉｎｇ Ｌｉｍｉｔｅｄ MHC class I-related peptides for the prevention and treatment of multiple flaviviruses
US20220001001A1 (en) * 2018-07-13 2022-01-06 University Of Georgia Research Foundation Broadly reactive immunogens of dengue virus, compositions, and methods of use thereof
US11344614B2 (en) 2018-09-29 2022-05-31 Emergex Vaccines Holding Ltd. Pharmaceutical compositions comprising dengue virus-specific multiple HLA-binding T cell epitopes
US20230241205A1 (en) * 2020-06-17 2023-08-03 Tscan Therapeutics, Inc. Sars-cov-2 immunodominant peptides and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4844893A (en) 1986-10-07 1989-07-04 Scripps Clinic And Research Foundation EX vivo effector cell activation for target cell killing
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5635363A (en) 1995-02-28 1997-06-03 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for the detection, quantitation and purification of antigen-specific T cells
BR0315935A (en) * 2002-10-31 2005-09-20 Health Research Inc Diagnostic Test for West Nile Virus
US20080107668A1 (en) 2006-08-30 2008-05-08 Immunotope, Inc. Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
FR2906724B1 (en) * 2006-10-04 2009-03-20 Sanofi Pasteur Sa METHOD OF IMMUNIZATION AGAINST THE 4 SEROTYPES OF DENGUE.
EP2294192A4 (en) * 2008-06-09 2011-11-23 Jolla Inst Allergy Immunolog Compositions and methods for dengue virus (dv) treatment and vaccination
AU2010286940A1 (en) 2009-08-26 2012-03-08 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
GB201106069D0 (en) * 2011-04-11 2011-05-25 Isis Innovation Peptide markers and uses thereof
US9637521B2 (en) 2011-06-29 2017-05-02 Emergex Vaccines Holdings Limited Cytotoxic T lymphocyte inducing immunogens for prevention treatment and diagnosis of dengue virus infection
EP3228321B1 (en) 2011-09-13 2019-04-10 Immunotope, Inc. Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer

Also Published As

Publication number Publication date
SG195115A1 (en) 2013-12-30
WO2013003579A1 (en) 2013-01-03
US10144766B2 (en) 2018-12-04
US20190106462A1 (en) 2019-04-11
US9637521B2 (en) 2017-05-02
AU2012275319A1 (en) 2013-11-14
BR112013032421A2 (en) 2017-01-17
US20140105925A1 (en) 2014-04-17
US10556929B2 (en) 2020-02-11
US20170275338A1 (en) 2017-09-28

Similar Documents

Publication Publication Date Title
SG10201704908SA (en) Cytotoxic T-Lymphocyte-Inducing Immunogens For Prevention, Treatment, And Diagnosis Of Dengue Virus Infection
AP3069A (en) Thienopyridine derivatives for the treatment and prvention of dengue virus infection
ZA201308617B (en) Use of thiazolide compounds for the prevention and treatment of viral diseases, cancer and diseases caused by intracellular infections
PL2740793T3 (en) Drug composition for cancer treatment and/or prevention
EP2596741A4 (en) Endoscope, and treatment instrument for endoscope
EP2470200A4 (en) Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
IL234116B (en) Composition having sialidase activity for treatment of parainfluenza virus in immunocomprimised patients
HK1212905A1 (en) Vaccine compositions for prevention against dengue virus infection
MY168959A (en) Vaccine compositions for the prevention of dengue virus infection
EP2671586A4 (en) Drug therapy for preventing or treating glaucoma
ZA201303610B (en) Novel cyclosporin derivatives for the treatment and prevention of a viral infection
IL222890A0 (en) Medicaments for the treatment of il-1beta related conditions
ZA201203281B (en) Pharmaceutical combinations, pharmaceutical compositions, medicament and method for the treatment of animals
HK1248535A1 (en) Treatment or prevention of infection
EP2928470A4 (en) Thienopyridine derivatives for the treatment and prevention of dengue virus infections
HK1201123A1 (en) Hexadecyloxypropyl cidofovir for the treatment of double-stranded dna virus infection
GB0906159D0 (en) Drug combination for the treatment of proteostatic diseases
EP2554189A4 (en) Blood treatment filter
EP2601967A4 (en) Drug and method for the prophylaxis of hiv infection and for the prophylaxis and treatment of diseases caused by or associated with hiv, including aids
GB201207543D0 (en) Treatment of transfusion blood
BR112014003556A2 (en) virus treatment method and pharmaceutical composition
GB201121940D0 (en) Drug treating high blood pressure
EP2522360A4 (en) Vaccine for treatment of tautopathy
IL225755A0 (en) 6-amido derivatives of 4,5a-epoxymorphinans for treatment of pain
ZA201307019B (en) Compositions for preventing and/or treating and infection by an hiv-1 virus